Radiotherapy, tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion chemotherapy of RALOX versus FOLFOX for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score-matching cohort study
The RALOX-HAIC combined radiotherapy, TKI, and ICI may provide similar survival advantages with fewer treatment-related abdominal pain and fever compared to FOLFOX-HAIC for HCC patients with PVTT. The prealbumin < 170 mg/L before therapy is an independent risk factor for OS.
Authors
- Hao-Yang Tan (ORCID: https://orcid.org/0000-0001-5739-378X)
- Hua-Guo Feng (ORCID: https://orcid.org/0000-0002-4669-1703)
- Yanhan Liu (ORCID: https://orcid.org/0000-0001-5284-2144)
- Shuangquan Liu (ORCID: https://orcid.org/0000-0002-2690-2665)
- Jiu-Ling Zheng
- Guohua Dai
Institutions
- Chongqing University (CN)
- Jiangjin Central Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1007/s12672-025-02553-9
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Chongqing University